Eli Lilly and Company
ANTI-TIM-3 ANTIBODIES FOR COMBINATION WITH ANTI-PD-L1 ANTIBODIES
Last updated:
Abstract:
The present invention relates to antibodies that bind human T-cell immunoglobulin- and mucin-domain-containing protein-3 (Tim-3), and may be useful for treating solid and hematological tumors in combination with anti-human PD-L1 antibodies, chemotherapy, and ionizing radiation.
Status:
Application
Type:
Utility
Filling date:
1 Dec 2017
Issue date:
23 Jan 2020